Literature DB >> 18439674

JAK2-V617F and BCR-ABL--double jeopardy?

Alwin Krämer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18439674     DOI: 10.1016/j.leukres.2008.03.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

2.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

3.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

4.  Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Jan Samuelsson; Ola Landgren
Journal:  Genome Med       Date:  2009-05-29       Impact factor: 11.117

5.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.